Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 June 2023Website:
http://www.fortrea.comNext earnings report:
11 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 21:58:33 GMTDividend
Analysts recommendations
Institutional Ownership
FTRE Latest News
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.24 per share a year ago.
For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 million GAAP net loss of $(18.5) million Adjusted EBITDA of $64.2 million GAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectively Book-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the third quarter ended September 30, 2024.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What type of business is Fortrea Holdings?
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
What sector is Fortrea Holdings in?
Fortrea Holdings is in the Healthcare sector
What industry is Fortrea Holdings in?
Fortrea Holdings is in the Biotechnology industry
What country is Fortrea Holdings from?
Fortrea Holdings is headquartered in United States
When did Fortrea Holdings go public?
Fortrea Holdings initial public offering (IPO) was on 20 June 2023
What is Fortrea Holdings website?
https://www.fortrea.com
Is Fortrea Holdings in the S&P 500?
No, Fortrea Holdings is not included in the S&P 500 index
Is Fortrea Holdings in the NASDAQ 100?
No, Fortrea Holdings is not included in the NASDAQ 100 index
Is Fortrea Holdings in the Dow Jones?
No, Fortrea Holdings is not included in the Dow Jones index
When was Fortrea Holdings the previous earnings report?
No data
When does Fortrea Holdings earnings report?
The next expected earnings date for Fortrea Holdings is 11 March 2025